Prevention of bone marrow failure in fanconi anemia through fancm inhibition

The Defense Health Agency (DHA) awarded $591,096 to St. Vincent's Institute of Medical Research under the Military Medical Research and Development program (CFDA 12.420) on July 15, 2025, for the project titled "Prevention of Bone Marrow Failure in Fanconi Anemia Through FANCM Inhibition." The award supports a three-year research initiative concluding July 14, 2028, focused on developing innovative therapeutic interventions for Fanconi anemia, a critical genetic disorder. The research aims to advance gene correction techniques and in vivo delivery methods for genetic disorder treatments, with potential applications benefiting both military service members and the broader public healthcare community.

As a non-profit biomedical research institution based in Australia, St. Vincent's Institute will conduct hypothesis-driven research investigating FANCM inhibition as a mechanism to prevent bone marrow failure associated with Fanconi anemia. This project aligns with the Military Medical Research and Development program's emphasis on advanced biomedical research addressing critical health challenges through translational studies and novel therapeutic development. The research deliverables will contribute to the program's overarching objective of transforming healthcare through cutting-edge medical innovations with potential military and civilian relevance.